ClinicalTrials.gg
RecruitingNCT05745623Updated Sep 11, 2025

Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

A Phase 1/2 interventional study of ICP-723 in Advanced Solid Tumors Harboring NTRK Fusion and Primary Central Nervous System Tumors Harboring NTRK Fusion, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Central Nervous System Neoplasms with a site in China — 4 open to participants now, 7 under way, none of them phase 3. Central Nervous System Neoplasms · China.

Started
2022
with 2 others
Phase 1/2
4 of 11
1 open now
Registered
9th of 11
by date
Lead sponsor
1 of 11
Beijing InnoCare Pharma Tech Co., Ltd.

Among the 11 studies in Central Nervous System Neoplasms with a site in China, this one is one of 3 that started in 2022, is one of 4 in phase 1/2, and was the 9th registered.

Central Nervous System Neoplasms

699 studies on the registry are indexed under Central Nervous System Neoplasms; 65 are open to participants now.

Browse Central Nervous System Neoplasms studies →

Open to participants now

4 of the 11 studies in Central Nervous System Neoplasms with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 56 Central Nervous System Neoplasms studies recruiting now, 34 (61%) set no upper age limit and 19 (34%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Central Nervous System Neoplasms with a site in China, or all of them as a file.
02

Study summary

A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors

03

Conditions studied

  • Advanced Solid Tumors Harboring NTRK Fusion
  • Primary Central Nervous System Tumors Harboring NTRK Fusion
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (ECOG) performance status of 0-1;
  2. Patients with advanced solid tumors or primary central nervous system (CNS) tumors harboring NTRK gene fusions as detected by the designated central laboratory, who received no previous NTRK inhibitor treatment;
  3. At least one as per RECIST1.1 criteria, or for primary CNS tumors, at least one measurable lesion as per RANO or INRC criteria.
  4. Organ functions meet the clinical criteria

Exclusion criteria

Exclusion Criteria:

  1. Patients with unstable primary central nervous system (CNS) tumors or .
  2. Patients with abnormal at screening, or other abnormalities in electrocardiographic examination at the discretion of the investigator.
  3. Patient with recent anti-tumor and other treatment as stated in the protocol.
  4. Grade 1 or higher toxicities attributed to any previous treatment not yet recovered.
  5. Other conditions considered unsuitable for participation in this trial at the discretion of the investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    ICP-723

    Drug: ICP-723

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    The objective response rate (ORR) evaluated by the Independent Center Review

    Time frame: Through study completion, an average of 4 years

Secondary outcomes

  1. ORR assessed by the investigator

    Time frame: Through study completion, an average of 4 years

  2. DCR as assessed by the investigator and the IRC

    Time frame: Through study completion, an average of 4 years

  3. Time to response (TTR) as assessed by the investigator and the IRC

    Time frame: Through study completion, an average of 4 years

  4. Duration of response (DOR) as assessed by the investigator and the IRC

    Time frame: Through study completion, an average of 4 years

  5. Progression-free survival (PFS) as assessed by the investigator and the IRC

    Time frame: Through study completion, an average of 4 years

  6. Intracranial objective response rate (IC-ORR) as assessed by the investigator and IRC

    Time frame: Through study completion, an average of 4 years

  7. central nervous system progression-free survival (CNS-PFS) as assessed by the investigator and IRC

    Time frame: Through study completion, an average of 4 years

  8. Overall survival (OS)

    Time frame: Through study completion, an average of 4 years

  9. The incidence, character and severity of adverse events as assessed per NCI-CTCAE v5.0 criteria

    Time frame: Through study completion, an average of 4 years

  10. The maximum plasma concentration observed (Cmax)

    Time frame: Through study completion, an average of 4 years

  11. Time of maximum observed plasma concentration (Tmax)

    Time frame: Through study completion, an average of 4 years

  12. Elimination half-life (t1/2)

    Time frame: Through study completion, an average of 4 years

  13. AUC0-∞

    Time frame: Through study completion, an average of 4 years

  14. AUC0-t

    Time frame: Through study completion, an average of 4 years

  15. Apparent clearance (CL/F)

    Time frame: Through study completion, an average of 4 years

  16. Apparent volume of distribution (Vz/F)

    Time frame: Through study completion, an average of 4 years

Other outcomes

  1. Colony-stimulating factor (CSF) concentrations

    Time frame: Through study completion, an average of 4 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2027, 59 months after the start.

Of 35 phase 1/2 interventional studies under Central Nervous System Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 85. This study's planned 59 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2023
First posted
Feb 27, 2023
StartActual
Dec 27, 2022
Primary completionEst.
Dec 25, 2027
CompletionEst.
Dec 25, 2028
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05745623
Responsible party
Sponsor
First posted
Feb 27, 2023
Start date
Dec 27, 2022
Primary completion
Dec 25, 2027 (estimated)
Completion
Dec 25, 2028 (estimated)
Last update
Sep 11, 2025

Study contacts

Ruihua Xu
Contact
xurh@sysucc.org.cn
020-87343333
Yuhong Li
Contact
liyh@sysucc.org.cn
Ruihua Xu
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zurletrectinib

Start the discussion